Humacyte is trading at $0.65, down -5.31%, while underperforming a stronger market and biotech sector, potentially reflecting profit-taking or concerns over losses, cash burn, and sub-$1 trading. - No fresh negative company announcement clearly explains the August 21 decline. - Recent V007 Phase 3 results in The Lancet Digital Health showed ATEV superiority, but preceded today’s selling. - A director purchased 30,000 shares on August 17, reported August 19.